# A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

> **NCT03835819** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 18 (actual)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** IMGN853

## Key facts

- **NCT ID:** NCT03835819
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-02
- **Primary completion:** 2024-06-04
- **Final completion:** 2027-05-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-05-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03835819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03835819, "A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03835819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*